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Mutations in components of the 30 mRNA splicing machinery are found in almost 50% of myelodysplastic
syndrome (MDS) cases. In this issue of Cancer Cell, Kim and colleagues, Colla and colleagues, and Shirai
and colleagues report on the impact of mutated or dysregulated splicing factors to hematopoiesis, mRNA
splicing, and MDS pathogenesis.Among the most unexpected findings of
unbiased genome and exome sequencing
studies in cancer has been the identifica-
tion of highly recurrent somatic mutations
in genes encoding components of the 30
pre-mRNA splicing machinery in myelo-
dysplastic syndrome (MDS), chronic lym-
phocytic leukemia, and various solid tu-
mors (Papaemmanuil et al., 2011; Rossi
et al., 2011; Yoshida et al., 2011). The
spliceosome is composed of five small
nuclear ribonucleoproteins (snRNPs) and
over 200 proteins (Wahl et al., 2009). It
regulates the alternative splicing of over
95% of multiexonic genes and is essential
for normal cellular development. Although
intron-exon splice site boundaries are
short and degenerate, the precise RNA-
RNA, RNA-protein, and protein-protein
interactions that are orchestrated by
normal spliceosome assembly and func-
tion lead to tissue-specific gene expres-
sion of particular transcripts.
In MDS, somatic mutations in compo-
nents of the 30 pre-mRNA splicing ma-
chinery commonly alter specific ‘‘hot
spot’’ amino acids and often occur as
early pathogenic events. The mutations
are invariably heterozygous and aremutu-
ally exclusive with other spliceosome
mutations. Three reports in this issue of
Cancer Cell characterize the effects of
dysregulation of specific splicing factors
on normal hematopoiesis. Kim et. al.
(2015) generated a hematopoietic-spe-
cific conditional Srsf2 knock-in mouse
with the most common SRSF2 mutation,
P95H (Srsf2P95H); Shirai et. al. (2015)
made a doxycycline-inducible transgenic
mouse model of the most common
U2AF1 mutation, S34F (U2AF1S34F); and
Colla et. al. (2015) used an inducible telo-
merase reverse transcriptase-estrogenreceptor (TERTER) murine model to
demonstrate that telomerase deficiency
induces myelodysplasia by dysregulating
expression of wild-type Srsf2 as well as
other 30 spliceosome components.
SRSF2 is a member of the serine/argi-
nine-rich protein family. It promotes
exon recognition by binding to exonic
splicing enhancer sequences (ESEs)
near the 50 or 30 splice site through its
RNA recognition motif domain (RRM).
U2AF1 binds to AG dinucleotides at the
30 end of the intron and assists in recruit-
ment of the U2 snRNP for spliceosome
activation. Telomerase function had not
previously been linked to splicing dysre-
gulation in MDS.
An initial question is whether the genetic
lesions studied induce the hematologic
phenotype of MDS. All of the models
have differentiation defects consistent
withMDS,eachwithadistinct hematologic
phenotype (Figure 1). Srsf2P95H mice
develop leukopenia and a macrocytic
anemia with bone marrow dysplasia and
increased hematopoietic stem cells.
U2AF1S34F transgenic mice developed
leukopenia, without anemia or dysplasia,
and increased hematopoietic stem and
myeloid progenitor cells. Fourth and fifth
generationTERTER/ERmice develop leuko-
penia withmarked lymphopenia, mild ane-
mia, a hypercellular bonemarrow with trili-
neagedysplasia, increasedmyeloidblasts,
and increased hematopoietic stem and
myeloid progenitor cells. Whereas neither
the Srsf2P95H nor the U2AF1S34F mice
developed acute myeloid leukemia (AML),
approximately 5% of the TERTER/ER mice
developed AML. In all models, mutant
stem cells have a competitive disadvan-
tage when compared to wild-type stem
cells in competitive repopulation assays.Cancer CelA second question is whether the mu-
tations have specific effects on mRNA
splicing. Each group of investigators
compared the transcriptomes of hemato-
poietic cells from their murine models
to human AML cell lines and/or MDS
or AML patient samples and identified
changes in exon recognition or de-
creased spliceosome protein expres-
sion. Kim et al. (2015) analyzed RNA
sequencing data to identify motifs asso-
ciated with mutant-specific splicing alter-
ations and found that mutant SRSF2 has
altered, rather than a loss of normal, ESE
recognition activity. Wild-type SRSF2
recognizes the consensus binding se-
quences CCNG and GGNG with similar
affinity (Daubner et al., 2012), whereas
SRSF2P95H appears to preferentially
bind CCNG within exons that were defer-
entially spliced. Similarly, Shirai et al.
(2015) analyzed RNA sequencing data
to identify a splice junction sequence-
specific pattern of altered splicing
induced by mutant U2AF1. Exons skip-
ped more frequently and alternative
splice sites used more often than ca-
nonical splice sites by U2AF1S34F were
enriched for a uracil in the minus 3
position relative to the AG dinucleotide.
These findings are consistent with pub-
lished reports of mutant U2AF1-associ-
ated splicing abnormalities in lung cancer
and myeloid malignancies (Brooks et al.,
2014). Colla et al. (2015) found that telo-
merase dysfunction caused decreased
expression of genes involved in 30-
mRNA splice site recognition and that
this was associated with abnormal
splicing. 40% of the aberrant splicing
events in TERTER/ER cells resulted in
exon skipping, and 59.5% of aberrant
splicing events resulted in exon retention.l 27, May 11, 2015 ª2015 Elsevier Inc. 607
Figure 1. Summary of the Splicing Alterations andHematopoietic Findings in ThreeMouseModels of Altered SplicesosomeProtein Function
Mouse models of mutant Srsf2 and U2AF1 identified mutant-specific binding preferences and alternative splicing events promoted by the mutant proteins as
shown. TERTER/ER mice have decreased expression of several splicing factors including SRSF2. MDS-associated genes reported to be aberrantly spliced in
each model system and the effects of each mutation on hematopoiesis are also indicated. 50 ss, 50 splice site; 30 ss, 30 splice site.
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PreviewsThe biochemical alterations in spliceo-
some activity were studied in most detail
by Kim et al. (2015), who transcriptionally
profiled cell lines with expression of
wild-type or mutant SRSF2 or cells with
shRNA-mediated decreased expression
of SRSF2. They found that knock-down
of SRSF2 results in preferential skipping
of exons with either C- or G-rich variants
of the consensus motif, overexpression of
wild-type SRSF2 results in inclusion of
exons with enrichment of both C- and G-
rich consensus motifs, and expression of
mutant SRSF2 results in enrichment of
CCNG in included exons and enrichment
of GGNG in excluded exons. They further
showed that these differences are due to
changes in SRSF2:RNA interactions using
isothermal titration calorimetry to examine
the binding affinity of purified RNA li-
gands to purified RRM from wild-type or
P95 mutant SRSF2. Consistent with their
motif analysis, P95 mutants have an
increased binding affinity for CCNG-con-
tainingRNA ligands andadecreasedbind-
ing affinity for GGNG-containing RNA
ligands compared to wild-type SRSF2.608 Cancer Cell 27, May 11, 2015 ª2015 ElsAn overarching question is whether
the oncogenic impact of mutant splicing
factor genes is caused by aberrant
splicing of one specific gene in partic-
ular, the integrated effects of altered
splicing of a large number of genes, or
a biological consequence of the muta-
tions that is independent of mRNA
splicing. In the case of SRSF2 mutations,
Kim et al. (2015) showed that one func-
tional consequence of mis-splicing in
SRSF2 mutant cells is the inclusion of a
‘‘poison’’ exon in the mRNA of EZH2,
which encodes a histone H3K27 methyl-
transferase and is commonly mutated in
MDS (Nikoloski et al., 2010). This ‘‘poi-
son’’ exon contains the CCNG motif
required for robust splicing by mutant
SRSF2 and introduces a premature
termination codon in EZH2 mRNA that
results in nonsense-mediated decay of
the EZH2 transcript. They demonstrated
that EZH2 protein and H3K27me3 levels
are lower in SRSF2 mutant cells and that
EZH2 loss-of-function mutations are
mutually exclusive with SRSF2mutations
in MDS. They also showed that over-evier Inc.expression of properly spliced EZH2
cDNA in progenitor cells from Srsf2P95H
mice partially rescues the hematopoietic
defect induced by mutant SRSF2 in
methylcellulose colony assays. Similarly,
mutant U2AF1-induced splice isoform
changes occur in disease-relevant genes
including BCOR, GNAS, and PICALM.
Among other alterations in splicing,
Colla et al. (2015) found telomerase
dysfunction caused aberrant splicing of
Dnmt3a.
In aggregate, the findings described
in these papers are a major advance to-
ward understanding how alterations in
the spliceosome alter the transcriptome,
hematopoietic differentiation, and he-
matopoietic stem cell function in MDS.
The three studies describe genetic lesions
affecting spliceosome function that lead
to distinct abnormalities in mRNA splicing
and features of MDS. Further studies us-
ing these and other models of MDS will
help to identify functionally important tar-
gets of mis-splicing as well as the genes
that cooperate with spliceosome muta-
tions in MDS. Therapeutic agents are
Cancer Cell
Previewscurrently in development to target aber-
rant spliceosome function in MDS and
other malignancies, and these models
will be invaluable for pre-clinical testing
of these drugs.
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In this issue ofCancer Cell, Polprasert and colleagues identified recurrent mutations in the DEAD/H-box RNA
helicase gene DDX41 in familial and acquired cases of myelodsyplasia and acute myeloid leukemia. These
mutations induce defects in RNA splicing and represent a new class of mutations in myeloid malignancies.The familial myelodysplastic (MDS)/acute
myeloid leukemia (AML) syndromes
belong to a group of rare inherited disor-
ders that represent a unique resource to
study the initial steps toward leukemia
progression. Recent findings indicate
that AML occurs after a stepwise pro-
cess of genetic and epigenetic changes,
some of which are ancestral and are
found in a preleukemic clone that pre-
cedes the fully transformed AML cells
bearing additional alterations (Pandolfi
et al., 2013). In familial MDS/AML, the
initial germline mutation can be consid-
ered a preleukemic event, required but
not sufficient for leukemia initiation.
Among the most studied ones are familial
AML with mutated CEBPA, familial MDS/
AML with GATA2 mutations, and familial
platelet disorder with predisposition to
AML (FPD/AML) due to RUNX1 muta-
tions (West et al., 2014). Interestingly,
mutations in these transcription factorsalso play important roles in sporadic
AML, showing that, in principle, both
germline and acquired mutations of the
same genes can deregulate the hemato-
poietic compartment and lead to AML
development. Thus, the study of patients
with familial MDS/AML has proven to be
extremely valuable for understanding the
multi-step leukemogenic process (Ant-
ony-Debre´ et al., 2015), including in spo-
radic leukemias.
The advent of whole exome sequencing
technology is of great interest for the
identification of new mutations in familial
MDS/AML syndromes, because the ge-
netic origin of many of them remains
unknown. A better knowledge of these
syndromes would be beneficial not only
for research, but also for clinical care,
as individuals harboring familial muta-
tions could be identified, e.g., for more
frequent follow-up examinations or for
exclusion when a bone marrow allograftis considered. In this issue of Cancer
Cell, Polprasert et al. (2015) identified
functionally relevant mutations in the
gene coding for the DEAD/H-box RNA
helicase DDX41 in both familial and
sporadic MDS/AML cases. Initially, they
discovered inherited DDX41 mutations in
several MDS/AML pedigrees and showed
that additional somatic DDX41 mutations
of the remaining wild-type allele were pre-
sent at MDS/AML diagnosis in half of the
cases (Figure 1A). This is similar to what
has been observed in MDS/AML with
CEBPA or RUNX1 mutations, where bial-
lelic mutations are found with AML pro-
gression (Pabst et al., 2008; Preudhomme
et al., 2009). The clonal architecture of
leukemic clones revealed that acquired
DDX41 mutations could be a founder
event in some patients. Familial DDX41
MDS/AML syndrome was characterized
by a long latency, an advanced stage at
diagnosis (high risk MDS/AML), normall 27, May 11, 2015 ª2015 Elsevier Inc. 609
